097. Face perception task: To assess the influence of oxytocin on face perception, two versions of a face matching test were created (see Fig. 1B). This test was click here designed to measure participants’ ability to match faces of the same identity, without placing any demands on long-term face memory. Each version of the test contained 40 trials in which a target face was positioned at the top of the screen,

and a triad of test images was placed below. Participants were instructed to select the test image that matched the identity of the person displayed in the target image. Forty male and 40 female facial identities were selected from the Bosphorus Face Database ( Savran, Sankur, & Bilge, 2012), and different facial identities were used in the two versions of the test (20 male and 20 female in each). All faces displayed

neutral expressions and were cropped to exclude any external features that might aid performance. In each trial, the target image was displayed from a frontal perspective, and was reduced in size and darkened in colour from the test images, to prevent participants using low-level visual properties of the images to aid performance. Head direction of the test images was varied across the trials. Specifically, in each version, eight trials CYC202 chemical structure displayed faces from each of a frontal, 1/3 left profile, 1/3 right profile, a tilted-upwards and a tilted-downwards perspective. The same participants as described above completed a pilot test to ensure the two versions were of equal difficulty, and no difference in scores was noted (version 1: M = 31.20, SE = 1.03; version

2: M = 30.95, SE = .77), F(1,18) = .080, p = .781, ƞp2 = .004. Again, scores were not influenced by order of completion, F(1,18) = .119, p = .734, ƞp2 = .007 and F(1,18) = .157, p = .697, ƞp2 = .009. Participants this website were asked to abstain from food and drink other than water for 2 h before the experiment; and from alcohol, smoking and caffeine for 24 h before the experiment. Each participant visited the laboratory on two occasions, separated by a 14–25 (M = 16.55, SD = 5.07) day interval, dependent on participant availability. The length of the interval between testing sessions did not vary for DP compared to control participants, F(1,18) = .690, p = .417 ƞp2 = .037. On each visit, participants received a single intranasal dose of 24 IU oxytocin (Syntocinon Spray, Novartis; three puffs per nostril, each with 4 IU oxytocin) or placebo spray. The placebo spray was prepared by an independent pharmaceutical company, and contained exactly the same ingredients as the experimental spray with the exception of the oxytocin. Preparation of the sprays by an independent company also ensured the experiment was double-blind, and the two sprays were identified by colour rather than their actual identity (i.e., oxytocin or placebo), which was only revealed after data analysis was complete.